187 related articles for article (PubMed ID: 22887470)
1. Characterization of estrogen-receptor-targeted contrast agents in solution, breast cancer cells, and tumors in vivo.
Pais A; Biton IE; Margalit R; Degani H
Magn Reson Med; 2013 Jul; 70(1):193-206. PubMed ID: 22887470
[TBL] [Abstract][Full Text] [Related]
2. In vivo magnetic resonance imaging of the estrogen receptor in an orthotopic model of human breast cancer.
Pais A; Gunanathan C; Margalit R; Biton IE; Yosepovich A; Milstein D; Degani H
Cancer Res; 2011 Dec; 71(24):7387-97. PubMed ID: 22042793
[TBL] [Abstract][Full Text] [Related]
3. Estrogen Receptor-Targeted Contrast Agents for Molecular Magnetic Resonance Imaging of Breast Cancer Hormonal Status.
Pais A; Degani H
Front Oncol; 2016; 6():100. PubMed ID: 27200289
[TBL] [Abstract][Full Text] [Related]
4. Water-soluble contrast agents targeted at the estrogen receptor for molecular magnetic resonance imaging.
Gunanathan C; Pais A; Furman-Haran E; Seger D; Eyal E; Mukhopadhyay S; Ben-David Y; Leitus G; Cohen H; Vilan A; Degani H; Milstein D
Bioconjug Chem; 2007; 18(5):1361-5. PubMed ID: 17784729
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic Value of ER, PR, FR and HER-2-Targeted Molecular Probes for Magnetic Resonance Imaging in Patients with Breast Cancer.
Jin YH; Hua QF; Zheng JJ; Ma XH; Chen TX; Zhang S; Chen B; Dai Q; Zhang XH
Cell Physiol Biochem; 2018; 49(1):271-281. PubMed ID: 30138940
[TBL] [Abstract][Full Text] [Related]
6. Tumor-Microenvironment Relaxivity-Changeable Gd-Loaded Poly(L-lysine)/Carboxymethyl Chitosan Nanoparticles as Cancer-Recognizable Magnetic Resonance Imaging Contrast Agents.
Jiang D; Zhang X; Yu D; Xiao Y; Wang T; Su Z; Liu Y; Zhang N
J Biomed Nanotechnol; 2017 Mar; 13(3):243-54. PubMed ID: 29381026
[TBL] [Abstract][Full Text] [Related]
7. Quantitative Molecular Imaging with a Single Gd-Based Contrast Agent Reveals Specific Tumor Binding and Retention in Vivo.
Johansen ML; Gao Y; Hutnick MA; Craig SEL; Pokorski JK; Flask CA; Brady-Kalnay SM
Anal Chem; 2017 Jun; 89(11):5932-5939. PubMed ID: 28481080
[TBL] [Abstract][Full Text] [Related]
8. Redox ferrocenylseleno compounds modulate longitudinal and transverse relaxation times of FNPs-Gd MRI contrast agents for multimodal imaging and photo-Fenton therapy.
Zhou T; Zhang S; Zhang L; Jiang T; Wang H; Huang L; Wu H; Fan Z; Jing S
Acta Biomater; 2023 Jul; 164():496-510. PubMed ID: 37054962
[TBL] [Abstract][Full Text] [Related]
9. Structural effect on degradability and in vivo contrast enhancement of polydisulfide Gd(III) complexes as biodegradable macromolecular MRI contrast agents.
Zong Y; Wang X; Jeong EK; Parker DL; Lu ZR
Magn Reson Imaging; 2009 May; 27(4):503-11. PubMed ID: 18814987
[TBL] [Abstract][Full Text] [Related]
10. Peptide targeted tripod macrocyclic Gd(III) chelates for cancer molecular MRI.
Zhou Z; Wu X; Kresak A; Griswold M; Lu ZR
Biomaterials; 2013 Oct; 34(31):7683-93. PubMed ID: 23863450
[TBL] [Abstract][Full Text] [Related]
11. New dual mode gadolinium nanoparticle contrast agent for magnetic resonance imaging.
Ghaghada KB; Ravoori M; Sabapathy D; Bankson J; Kundra V; Annapragada A
PLoS One; 2009 Oct; 4(10):e7628. PubMed ID: 19893616
[TBL] [Abstract][Full Text] [Related]
12. Targeted Contrast Agents for Magnetic Resonance Molecular Imaging of Cancer.
Lu ZR; Laney V; Li Y
Acc Chem Res; 2022 Oct; 55(19):2833-2847. PubMed ID: 36121350
[TBL] [Abstract][Full Text] [Related]
13. Protein-targeted gadolinium-based magnetic resonance imaging (MRI) contrast agents: design and mechanism of action.
Caravan P
Acc Chem Res; 2009 Jul; 42(7):851-62. PubMed ID: 19222207
[TBL] [Abstract][Full Text] [Related]
14. A metastatic breast tumor cell line, GI-101A, is estrogen receptor positive and responsive to estrogen but resistant to tamoxifen.
Morrissey JJ; Raney S
Cell Biol Int; 1998; 22(6):413-9. PubMed ID: 10328849
[TBL] [Abstract][Full Text] [Related]
15. Improving Longitudinal Transversal Relaxation Of Gadolinium Chelate Using Silica Coating Magnetite Nanoparticles.
Xu K; Liu H; Zhang J; Tong H; Zhao Z; Zhang W
Int J Nanomedicine; 2019; 14():7879-7889. PubMed ID: 31576129
[TBL] [Abstract][Full Text] [Related]
16. Gd-hydroxypyridinone (HOPO)-based high-relaxivity magnetic resonance imaging (MRI) contrast agents.
Datta A; Raymond KN
Acc Chem Res; 2009 Jul; 42(7):938-47. PubMed ID: 19505089
[TBL] [Abstract][Full Text] [Related]
17. GdIII complexes with fast water exchange and high thermodynamic stability: potential building blocks for high-relaxivity MRI contrast agents.
Laus S; Ruloff R; Tóth E; Merbach AE
Chemistry; 2003 Aug; 9(15):3555-66. PubMed ID: 12898682
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and characterization of a porphyrazine-Gd(III) MRI contrast agent and in vivo imaging of a breast cancer xenograft model.
Trivedi ER; Ma Z; Waters EA; Macrenaris KW; Subramanian R; Barrett AG; Meade TJ; Hoffman BM
Contrast Media Mol Imaging; 2014; 9(4):313-22. PubMed ID: 24706615
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
